Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | HTR5A | P47898 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26847757 | 1.00 | MAPK1 (0.37) | MAPK1SPPL2ALMNAALDH1A1TSHR | |
| SCHEMBL25408472 | 0.79 | KMT2A (0.44) | SPPL2ALMNAALDH1A1TSHRHTT | |
| SCHEMBL26847744 | 0.79 | KMT2A (0.44) | SPPL2ALMNAALDH1A1TSHRHTT | |
| SCHEMBL30617078 | 0.79 | KMT2A (0.44) | SPPL2ALMNAALDH1A1TSHRHTT | |
| SCHEMBL25406983 | 0.69 | TIPARP (0.34) | MAPK1SPPL2ALMNANOTUM | |
| SCHEMBL25407200 | 0.68 | SPPL2A (0.42) | MAPK1SPPL2ALMNAALDH1A1HTR2C | |
| SCHEMBL25410662 | 0.68 | SPPL2A (0.42) | MAPK1SPPL2ALMNAALDH1A1HTR2C | |
| SCHEMBL25408208 | 0.67 | SPPL2A (0.56) | SPPL2ALMNA | |
| SCHEMBL25409891 | 0.67 | SPPL2A (0.56) | SPPL2ALMNA | |
| SCHEMBL26686720 | 0.67 | SPPL2A (0.56) | SPPL2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4578451-A2 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | Novartis AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| EP-4214210-B1 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | NOVARTIS AG (CH) | 2025-04-09 | — | — | EP | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | SPPL2A, SPPL2B, BACE1 | MAPK1 1689/4885SPPL2A 1/4885LMNA 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.